Beyond Air Inc Stock News

As the first Beyond Air luminary site, Vanderbilt will help evaluate and showcase the clinical and operational benefits of LungFit® PH, supporting broader awareness and adoption of tankless iNO technology As the first Beyond Air luminary site, Vanderbilt will help evaluate and showcase the clinical and operational benefits of LungFit® PH, supporting broader awareness and adoption of tankless iN...

First-in-human studies anticipated to begin in 2026 Engaged a top tier U.S. based contract manufacturer to ensure the highest standards of quality Currently in the advanced stages of formulation development for subcutaneous injection, with plans for an oral formulation BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company focused on developing transformativ...

Distribution agreements recently signed for France, Turkey, Romania and Morocco LungFit PH international distribution network now includes 18 countries Initial international orders for LungFit PH systems have been received for four countries GARDEN CITY, N.Y., March 11, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device an...

GARDEN CITY, N.Y., March 06, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in the Roth 37th Annual G...

Beyond Air, Inc. (NASDAQ:XAIR ) Q3 2025 Results Conference Call February 10, 2025 4:30 PM ET Company Participants Corey Davis - Investor Relations, LifeSci Advisors Steve Lisi - Chairman and Chief Executive Officer Doug Larson - Chief Financial Officer Conference Call Participants Jason Wittes - Roth Partners Sam Eiber - BTIG Jason Bednar - Piper Sandler Justin Walsh - JonesTrading Yale Jen - L...

Revenues increased 34% compared to the previous quarter ended September 30, 2024; and exceeded $1 million Received CE Mark for LungFit PH ® in Europe and Market Authorization in Australia; international shipments to commence later this year Conference call at 4:30 p.m. ET today, February 10 th GARDEN CITY, New York, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air”...

GARDEN CITY, N.Y., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced it received a notification from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has been granted...

GARDEN CITY, N.Y., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that it plans to report the financial results for the fiscal third quarter 2025 ended December 31, 2024 on Monda...